Complements of moneyduh #20014 (2/15/13 @ 4:27:31 PM):
Why this is skyrocketing.. Certainly, $ENTB will surpass $BMSN in share price very soon, as it has the better share structure. The most telling and revealing information gathered today was the PIVOTAL switch of $ENTB surpassing $BMSN in volume for the first time today BY OVER 5 MILLION SHARES! This indication has been unprecedented. Now, given they are the same company I see not ONE reason for them not to be trading at exactly the same price. I think next week people will realize $ENTB isn't just following the PATTERN of $BMSN but rather, collectively moving up either to match or pass it. In addition 120,000,000+ shares have been shorted here in just 1/2 the time that they were shorted here last month: http://otcshortreport.com/entb and LIKE I TOLD EVERYONE LAST TIME, it will cause a significant surge in share price. With the short squeeze already starting, it will be BRUTAL next week. Had they not had to cover on the 1st of February then certainly they will have to cover by the 20th next week! Additionally, with a 3 day weekend going into President's Day those short accounts are going to be charged for each day they are over. So in conclusion I think both stocks will be around .03-.10 realistically by the end of the month and then in March.. WE MARCH ! I wouldn't worry about news. This share increase has nothing to do with any news, as that's pretty much just a stock promoter thing. We're talking about an IND for the company as a whole and that's major and already documented and put in writing at www.otcmarkets.com/stock/bmsn/news So yeah my friend, I think we're going to do really well this year and should reach at least $1.50 by summer time as stated here: BTNSR releases $1.55 Price Target for $BMSN!!! http://biotechnewsstockreview.blogspot.com/2013/01/bio-matrix-scientific-group-bmsn-price.html -------------------------------------------- Saturday, January 26, 2013 Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review Bio-Matrix Scientific Group (BMSN) Price Target $1.55 By Summer_Investigational New Drug Application (IND) For HemaXellerate Turning Big Pharma Heads Forecasts Biotech News Stock Review. Adam feels that BMSN could quite possible become the stock of the year. Look for an epic run to begin after the filing of the IND and not stop until summer when the share price will hit $1.55. Lots of people are going to get rich off the back of BMSN.
About Biotech News Stock Review
Adam and Johnny both love investing in biotech stocks, especially small companies that have promising drug pipelines. Adam is an avid researcher and very meticulous in his stock selections, Adam previously worked for Sierra World Equity Review where he was fundamental in helping select numerous accurate FDA calls. Adam has a law degree from Yale and is also fluent in Mandarin which he studied at the University of Beijing. Johnny is a executive for a large pharmaceutical company based in New Jersey, with years of experience in his position as Managing Director for mergers and acquisitions with with special focus on China, Johnny brings valuable insight and perspective to the blogs daily stock posts. If you enjoy buying and selling stocks, occasionally trade stocks online and enjoy the thrill of seeing your stock breakout after positive FDA trial results, then perhaps you may enjoy our blog! To maintain impartiality we never hold positions in any of the stocks we blog about. Posted by Sierra World Equity Review at 10:44 PM -------------------------------------------- In conclusion with a pending short squeeze, IND, and news/financials to be released by end of this week we are looking at a MASSIVE increase in share price to take place. This will last into the next 3-4 months with many ups and downs but a consistent uptrend at least to $0.50 A measly $2,000 investment at .003 will become $333,333 at .50 -------------------------------------------- Entest BioMedical's ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous...
Entest BioMedical's ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous... PrintAlert Entest Biomedical Inc." (QB) (USOTC:ENTB) Intraday Stock Chart Today : Thursday 6 September 2012
Entest BioMedical Inc. (OTCQB: ENTB) a company focused on veterinary biotechnology and veterinary hospital acquisition / operation, announced today that the company's recent research study conducted on ImenVax™ (Entest's Immuno-therapeutic cancer vaccine for dogs), ImenVax™ appears to show signs of slowing tumor growth in advanced cases of oral melanoma, while being well tolerated by patients. "Principal investigators conducting the safety study on ImenVax™ observed the implantation device and vaccine to be very well-tolerated," stated Entest BioMedical Chairman & CEO David Koos. "There was only one case where the patient had a minor skin irritation. In all of the cases studied the size of the tumors were likely too extensive to allow for objective response with ImenVax™ as single agent therapy. The company's researchers stated that subjectively, tumor progression was slowed during the period that the implant was present and accelerated after removal in 2 patients. The report recommends that further evaluation in patients with lesser tumor burden is warranted, along with cytokine stimulation." Dr. Koos continued, "Our ImenVax™ immune-therapeutic cancer vaccine is designed to treat dogs with oral melanoma while limiting the side effects of treatment. We anticipate that within the next 16 months, we will have the capacity to treat just over 3,000 patients yearly throughout our veterinary clinics." A Spokesperson for the Company noted the National Canine Cancer Foundation says one in three dogs will be impacted by cancer. This staggering statistic shows not only the need for a cost effective treatment but also a treatment that is well tolerated. The potential revenue generated per patient is approximately $3,000 according to industry statistics. Management indicates that each veterinary hospital Entest will seek to acquire over the next two years will have a preexisting patient flow of at least 700 cancer patients per year. Once the first 10 veterinary hospitals have been acquired, Entest could possibly see 7,000 treatable canine patients per year at $3,000 per patient. This meaning, should Entest be successful in meeting its veterinary hospital acquisition target numbers [10 facilities], the company could potentially command revenues reflecting as much as $21 million per annum; treating dogs with cancer. Dr. Koos concluded, "Our ImenVax™ immuno-therapeutic cancer vaccine is being designed to utilize the patient's own immune system to battle the cancer; potentially making it a less invasive and less traumatic alternative for pet owners than chemotherapy and radiation therapy. Also, the safety study is being conducted on dogs suffering from oral melanoma. We have no intention to simply stop at oral melanoma applications. Entest is working with an incredibly experienced research team in hopes to increase efficacy in extreme cases by the inclusion of cytokine stimulation. We anticipate at some point in the near future, to begin clinical trials as we will ultimately seek USDA or FDA approval to further the reach of our ImenVax™ canine cancer treatment." About Entest BioMedical Inc.: Entest BioMedical Inc. (OTCQB: ENTB) is a developer of veterinary medicines that harness the animal's own reparative / immunological mechanisms. The company's products include an immuno-therapeutic cancer vaccine for canines (ImenVax™). The company's immuno-therapeutic cancer vaccine utilizes an encapsulation device as the vaccine delivery system and requires a simple implant procedure. Disclaimer This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. Contact:
Entest BioMedical Inc. David R. Koos Chairman & CEO 619.702.1404 Direct 619.330.2328 Fax Email Contact www.EntestBio.com -----------------------------------
"Men of genius are admired, men of wealth are envied, men of power are feared; but only men of character are trusted." Alfred Adler
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
